The CEO's sales are consistent with routine post-exercise liquidity and tax withholding, not a bearish signal. The EVP's sale is modest. Monitor next quarter's Tyvaso DPI growth trajectory and ralinepag NDA outcome for fundamental catalysts; insider activity alone does not warrant a trade.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 11 $515.50entry
- T+1 · 3mo ago −0.73%α −0.98% · $511.72
- T+5 · 3mo ago +0.54%α +0.94% · $518.27
- T+20 · 2mo ago −1.68%α −0.62% · $506.82
- T+60 · 13d ago +18.04%α +18.53% · $608.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Martine Rothblatt and EVP Paul Mahon sold a combined $989K in open-market shares within two days of United Therapeutics' Q2 2026 earnings, which showed a 2% revenue miss and 4% decline in total Tyvaso sales. While the dollar amount is trivial relative to the $22.7B market cap (0.004%), the timing, immediately after a mixed earnings report, and the CEO's exercise of 9,500 options for cashless net-share settlement suggest the sales are primarily liquidity-driven rather than a bearish signal. The cluster is neutral: the CEO's sales follow a typical post-exercise pattern, and the EVP's sale is modest. No material directional read-through for the stock.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 632 shares at $539.14, 625 at $538.54, and 2,781 at $531.30 among 14 open-market sales on 2026-08-07, totaling ~$4.6M
- CEO also exercised 9,500 options at $0 (non-cash) and 9,500 options at $135.42 (cash exercise of $1.29M) on the same day
- EVP Paul Mahon sold 1,360 shares at $515.93 and 780 shares at $517.94 on 2026-08-06, totaling ~$1.1M
- Total open-market sales by both insiders: ~$5.7M, or 0.025% of $22.7B market cap
- Q2 2026 revenue of $783.3M missed consensus of $804.6M; diluted EPS of $7.27 beat $6.86 estimate
Financial Impact
Insider sales total ~$5.7M, immaterial relative to $22.7B market cap (0.025%)
Risk Factors
- Revenue miss in Q2 2026 driven by 4% Tyvaso decline may pressure near-term sentiment
- CEO's large option exercise and concurrent sales could be misinterpreted as insider pessimism
- No buys in the cluster, absence of insider buying post-earnings is a mild negative
- Pipeline catalysts (ralinepag, Tyvaso IPF) are binary events with regulatory risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1786435291109 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers